<DOC>
	<DOCNO>NCT01106586</DOCNO>
	<brief_summary>To evaluate safety efficacy Stribild® , single tablet regimen ( STR ) contain fix dos elvitegravir ( EVG ) /cobicistat ( COBI [ GS-9350 ] ) /emtricitabine ( FTC ) /tenofovir disoproxil fumarate ( TDF ) versus ritonavir-boosted atazanavir ( ATV/r ) plus standard care nucleoside reverse transcriptase inhibitor ( NRTI ) backbone FTC/TDF ( Truvada® ) . ATV/r + FTC/TDF select active comparator study prefer protease inhibitor-based regimen guideline treatment HIV-1 infect , antiretroviral treatment-naive adult .</brief_summary>
	<brief_title>Study Evaluate Safety Efficacy Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada Human Immunodeficiency Virus , Type 1 ( HIV-1 ) Infected , Antiretroviral Treatment-Naive Adults</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Elvitegravir , Cobicistat , Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<criteria>Ability understand sign write informed consent form , must obtain prior initiation study procedure Plasma HIV1 RNA level ≥ 5,000 copies/mL screen No prior use approve investigational antiretroviral drug length time Screening genotype report must show sensitivity FTC , TDF , ATV Normal electrocardiogram ( ECG ) Adequate renal function ( estimate glomerular filtration rate ≥ 70 mL/min accord Cockcroft Gault formula ) Hepatic transaminase ( aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 5 x upper limit normal range ( ULN ) Total bilirubin ≤ 1.5 mg/dL , normal direct bilirubin Adequate hematologic function Serum amylase ≤ 5 x ULN Males Females childbearing potential must agree utilize highly effective contraception method screen throughout duration study treatment 30 day follow last dose study drug Age ≥ 18 year Life expectancy ≥ 1 year A new acquired immunodeficiency syndrome ( AIDS ) define condition diagnose within 30 day prior screen Receiving drug treatment hepatitis C , anticipate receive treatment hepatitis C Subjects experience decompensated cirrhosis Females breastfeed Positive serum pregnancy test ( female childbearing potential ) Implanted defibrillator pacemaker Current alcohol substance use judge Investigator potentially interfere subject study compliance History malignancy within past 5 year ongoing malignancy cutaneous Kaposi 's sarcoma , basal cell carcinoma , resect , noninvasive cutaneous squamous carcinoma Active , serious infection ( HIV1 infection ) require parenteral antibiotic antifungal therapy within 30 day prior baseline Medications contraindicate use EVG , COBI , FTC , TDF , ATV , ritonavir subject know allergy excipients Stribild tablet , Truvada tablet , ATV capsule ritonavir tablet Participation clinical trial without prior approval Any clinical condition prior therapy , opinion Investigator , would make subject unsuitable study unable comply dosing requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>HIV 1 Infection</keyword>
	<keyword>Treatment Naive</keyword>
</DOC>